Possibilities of non-invasive post-genomics technologies in the prediction and early diagnosis of preeclampsia
Objective. To search and analyze the literature devoted to the study of possible markers and predictors of preeclampsia (PE), with the use of post-genomics technologies in particular.Muminova K.T.
Material and methods. Articles were searched in the database Pubmed. The review includes the data of foreign and Russian articles published in the past 15 years.
Results. The markers identified so far are shown to relate to early PE. The paper presents the results of post-genomics studies based on omics technologies. It shows the possibility of using the urine congophilia phenomenon as a new screening method.
Conclusion. It is necessary to conduct further investigations to develop a panel of non-invasive markers for PE in biological fluids, by using a proteomic and further urinary peptidome analysis as an example, which, reflecting the multifactorial pattern of PE, can simultaneously serve as both a predictor and a tool for monitoring the course of the disease, being a key component of personalized medicine.
Keywords
preeclampsia
biomarkers
predictors
proteome
peptidome
endogenous peptides
mass spectrometry
antiogenic factors
omics technologies
urinary proteomic and peptidome analyses
congophilia
References
1. Pasha O., McClure E.M., Saleem S. et al. A Prospective Cause of Death Classification System for Maternal Deaths in Low and Middle-Income Countries: Results from the Global Network Maternal Newborn Health Registry. BJOG. 2017. [Epub ahead of print]
2. Kuklina E.V., Ayala C., Callaghan W.M. Hypertensive disorders and severe obstetric morbidity in the United States. Obstet. Gynecol. 2009; 113(6): 1299-306.
3. Raymond D., Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet. Gynecol. Surv. 2011; 66(8): 497-506.
4. Stubert J., Ullmann S., Dieterich M., Diedrich D., Reimer T. Clinical differences between early- and late-onset severe preeclampsia and analysis of predictors for perinatal outcome. J. Perinat. Med. 2014; 42(5): 617-27.
5. von Dadelszen P., Menzies J.M., Payne B., Magee L.A.; PIERS (Pre-eclampsia Integrated Estimate of RiSk) Study Group. Predicting adverse outcomes in women with severe pre-eclampsia. Semin. Perinatol. 2009; 33(3): 152-7.
6. Kucukgoz Gulec U., Ozgunen F.T., Buyukkurt S., Guzel A.B., Urunsak I.F., Demir S.C., Evruke I.C. Comparison of clinical and laboratory findings in early- and late-onset preeclampsia. J. Matern. Fetal Neonatal Med. 2013; 26(12): 1228-33.
7. Khodzhaeva Z.S., Kogan Y.A., Shmakov R.G., Klimenchenko N.I., Akatyeva A.S., Vavina O.V. Clinical and pathogenetic features of early- and late-onset pre-eclampsia. J. Matern. Fetal Neonatal Med. 2016; 29(18): 2980-6.
8. Lisonkova S., Joseph K.S. Incidence of preeclampsia: risk factors and outcomes associated with early- versus late-onset disease. Am. J. Obstet. Gynecol. 2013; 209(6): 544. e1-544. e12.
9. Bilano V.L., Ota E., Ganchimeg T., Mori R., Souza J.P. Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low- and middle-income countries: a WHO secondary analysis. PLoS One. 2014; 9(3): e91198.
10. Barton J., Sibai B. Prediction and prevention of recurrent preeclampsia. Obstet. Gynecol. 2008; 112(2, Pt 1): 359-72.
11. Lykke J.A., Langhoff-Roos J., Sibai B.M., Funai E.F., Triche E.W., Paidas M.J. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009; 53(6): 944-51.
12. Davis E.F., Lazdam M., Lewandowski A.J., Worton S.A., Kelly B., Kenworthy Y. et al. Cardiovascular risk factors in children and young adults born to preeclamptic pregnancies: a systematic review. Pediatrics. 2012; 129(6): 1552-61.
13. Simmons R.A. Developmental origins of adult disease. Pediatr. Clin North Am. 2009; 56(3): 449-66.
14. Martin A., Krishna I., Badell M. Can the quantity of cell-free fetal DNA predict preeclampsia: a systematic review. Prenat. Diagn. 2014; 34(7): 685-91.
15. Muñoz-Hernández R., Medrano-Campillo P., Miranda M.L., Macher H.C., Praena-Fernández J.M., Vallejo-Vaz A.J. et al. Total and fetal circulating cell-free DNA, angiogenic, and antiangiogenic factors in preeclampsia and HELLP syndrome. Am. J. Hypertens. 2017; 30(7): 673-82.
16. Allen R.E., Rogozinska E., Cleverly K., Aquilina J., Thangaratinam S. Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: a meta-analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014: 182: 194-201.
17. Stepan H., Kramer T., Faber R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J. Clin. Endocrinol. Metab. 2007; 92(7): 2831-4.
18. An Y., Goldman R. Analysis of peptides by denaturing ultrafiltration and LC-MALDI-TOF-MS. Methods Mol. Biol. 2013; 1023: 13-9.
19. Hsu T.Y., Hsieh T., Yang K.D., Tsai C.C., Ou C.Y., Cheng B.H. et al. Proteomic profiling reveals α1-antitrypsin, α1-microglobulin, and clusterin as preeclampsia-related serum proteins in pregnant women. Taiwan. J. Obstet. Gynecol. 2015; 54(5): 499-504.
20. Park J., Cha D.H., Lee S.J., Kim Y.N., Kim Y.H., Kim K.P. Discovery of the serum biomarker proteins in severe preeclampsia by proteomic analysis. Exp. Mol. Med. 2011; 43(7): 427-35.
21. Wen Q., Liu L.Y., Yang T., Alev C., Wu S., Stevenson D.K. et al. Peptidomic identification of serum peptides diagnosing preeclampsia. PLoS One. 2013; 8(6): e65571.
22. Dai X., Song X., Rui C., Meng L., Xue X., Ding H. et al. Peptidome analysis of human serum from normal and preeclamptic pregnancies. J. Cell. Biochem. 2017; 118(12): 4341-8.
23. Mary S., Kulkarni M.J., Malakar D., Joshi S.R., Mehendale S.S., Giri A.P. Placental proteomics provides insights into pathophysiology of pre-eclampsia and predicts possible markers in plasma. J. Proteome Res. 2017; 16(2): 1050-60.
24. Law K.P., Han T.L., Tong C., Baker P.N. Mass spectrometry-based proteomics for pre-eclampsia and preterm birth. Int. J. Mol. Sci. 2015; 16(5): 873-90.
25. Myers J.E., Tuytten R., Thomas G., Laroy W., Kas K., Vanpoucke G. et al. Integrated proteomics pipeline yields novel biomarkers for predicting preeclampsia. Hypertension. 2013; 61(6): 1281-8.
26. Anand S., Bench Alvarez T.M., Johnson W.E., Esplin M.S., Merrell K., Porter T.F., Graves S.W. Serum biomarkers predictive of pre-eclampsia. Вiomark. Med. 2015; 9(6): 563-75.
27. Kolialexi A., Tsangaris G.T., Sifakis S., Gourgiotis D., Katsafadou A., Lykoudi A. et al. Plasma biomarkers for the identification of women at risk for early-onset preeclampsia. Expert Rev. Proteomics. 2017; 14(3): 269-76.
28. Legge M., Duff G.B., Potter H.C., Hoetjes M.M. Maternal serum alpha 1-antitrypsin concentrations in normotensive and hypertensive pregnancies. J. Clin. Pathol. 1984; 37: 867-9.
29. Cid M.C., Grant D.S., Hoffman G.S., Auerbach R., Fauci A.S., Kleinman H.K. Identification of haptoglobin as an angiogenic factor in sera from patients with systemic vasculitis. J. Clin. Invest. 1993; 91(3): 977-85.
30. Olsson M.G., Allhorn M., Olofsson T., Akerström B. Up-regulation of α1-microglobulin by hemoglobin and reactive oxygen species in hepatoma and blood cell lines. Free Radic. Biol. Med. 2007; 42(6): 842-51.
31. Buhimschi I.A., Zhao G., Funai E.F., Harris N., Sasson I.E., Bernstein I.M. et al. Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia. Am. J. Obstet. Gynecol. 2008; 199(5): 551. e1-16.
32. Carty D.M., Siwy J., Brennand J.E., Zürbig P., Mullen W., Franke J. et al. Urinary proteomics for prediction of preeclampsia. Hypertension. 2011; 57(3): 561-9.
33. Kononikhin A.S., Starodubtseva N.L., Bugrova A.E., Shirokova V.A., Chagovets V.V., Indeykina M.I. et al. An untargeted approach for the analysis of the urine peptidome of women with preeclampsia. J. Proteomics. 2016; 149: 38-43.
34. Buhimschi I.A., Nayeri U.A., Zhao G., Shook L.L., Pensalfini A., Funai E.F. et al. Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. Sci. Transl. Med. 2014; 6(245): 245-92.
35. Hayden M.R., Tyagi S.C., Kerklo M.M., Nicolls M.R. Type 2 diabetes mellitus as a conformational disease. JOP. 2005; 6(4): 287-302.
36. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003; 300(5618): 486-9.
37. McCarthy F.P., Adetoba A., Gill C., Bramham K., Bertolaccini M., Burton G.J. et al. Urinary congophilia in women with hypertensive disorders of pregnancy and preexisting proteinuria or hypertension. Am. J. Obstet. Gynecol. 2016; 215(4): 464. e1-7.
38. Yung H.W., Atkinson D., Campion-Smith T., Olovsson M., Charnock-Jones D.S., Burton G.J. Differential activation of placental unfolded protein response pathways implies heterogeneity in causation of early- and late-onset preeclampsia. J. Pathol. 2014; 234(2): 262-76.
39. Jonas S.M., Deserno T.M., Buhimschi C.S., Makin J., Choma M.A., Buhimschi I.A. Smartphone-based diagnostic for preeclampsia: an mHealth solution for administering the Congo Red Dot (CRD) test in settings with limited esources. J. Am. Med. Inform. Assoc. 2016; 23(1): 166-73.
40. Mary S., Patil G.V., Kulkarni A.V., Kulkarni M.J., Joshi S.R., Mehendale S.S., Giri A.P. Dynamic proteome in enigmatic preeclampsia: an account of molecular mechanisms and biomarker discovery. Proteomics Clin. Appl. 2012; 6(1-2): 79-90.
Received 09.06.2017
Accepted 23.06.2017
About the Authors
Muminova Kamilla Timurovna, junior researcher, 1st obstetrical department of pathology of pregnancy, Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia. 117997, Russia, Moscow, Ac. Oparina str. 4. E-mail: kamika91@mail.ruFor citations: Muminova K.T. Possibilities of non-invasive post-genomics technologies
in the prediction and early diagnosis of preeclampsia.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (5): 5-10. (in Russian)
https://dx.doi.org/10.18565/aig.2018.5.5-10
Similar Articles
